Stock NOVN NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

News Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe
Other stock markets
 03:12:09 2024-04-16 am EDT 		5-day change 1st Jan Change
85.66 CHF -0.98% Intraday chart for Novartis AG +0.17% +1.92%
Apr. 12 Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug MT
Apr. 11 Health Care Slips on Risk Bias -- Health Care Roundup DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
AQ
MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
AQ
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
MT
Health Care Slips on Risk Bias -- Health Care Roundup
DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares
DJ
Novartis: licensing agreement in prostate cancer
CF
Novartis: MorphoSys Board recommends tender offer
CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins
MT
Morphosys management bodies recommend acceptance of Novartis takeover bid
DP
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion
RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer
CI
Novartis begins tender offer for cancer-focused MorphoSys
RE
NOVARTIS : UBS reiterates its recommendation on the stock
CF
Novartis Launches Tender Offer for Germany's MorphoSys
MT
Novartis initiates tender offer for MorphoSys
CF
Novartis begins tender offer for cancer-focused MorphoSys
RE
Novartis tender offer for MorphoSys AG commences
GL
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG